Market Research ReportJun 22, 2026

Immunoassays in R&D Market

Immunoassays in R&D Market Research Report: Size, Share, Trend Analysis By Product and Services (Kits and Reagents, Analyzers, Software And Services), By Application (Infectious Diseases, Cancer Research, Endocrinology, Autoimmune Diseases, Others), By Type (Enzyme-Linked Immunosorbent Assay (ELISA), Enzyme-Linked Immunospot Assay (ELISpot), RadioImmunoassay, Chemiluminescence, Fluoroimmunoassay, Others), By End User (Pharmaceutical Companies, Academic Institutions, Government Institutions) and By Region (North America, Europe, Asia Pacific, Rest of the World) - Growth Outlook & Industry Forecast To 2030

Vertical: HealthcareBase Year: 2021

Book Demo

Executive Summary

Immunoassays in R&D Market — Snapshot

Market Size (2021)
$19.77B
Projected (2030)
$34.73B
CAGR (2018–2030)
6.7%
Key Players
10+

Immunoassays are in-vitro tests that use antigen-antibody reaction to detect the concentrations of a wide range of biological substances in blood and other fluids. The market growth is majorly attributed to the growing prevalence of chronic and infectious diseases, growing technological advancements, and rising R&D expenditure by the private as well as public sector.

The global immunoassay in R&D market was valued at USD 4,752.5 million in 2017, and the market is estimated to grow at USD 7,716.6 million by 2023. In 2017, the Americas accounted for the largest market share of 38.85% with a market value of USD 1,846.5 million, followed by Europe with a market value of USD 1,537.7 million in 2017.

The global immunoassay in R&D market has been segmented into product and service, type, application, and end user. On the basis of product and service, the market has been segmented into kits and reagents, analyzers, and software and services.

The kits and reagents segment were the largest market segment, by product and service with a market value of USD 2,187.8 million in 2017.

On the basis of type, the market has been segmented into ELISA, Enzyme-Linked Immunospot Assay (ELISpot), radioimmunoassay (RIA), chemiluminescence (CLIA), Fluoroimmunoassay, and others. The ELISA segment was the largest market segment, by type with a market value of USD 1,520.0 million in 2017.

By application, the market has been segmented into infectious diseases, cancer research, endocrinology, autoimmune diseases, and others. The infectious disease segment was the largest market segment, by application with a market value of USD 1,471.2 million in 2017.

Based on end user, the market has been segmented into pharmaceutical and biotechnology companies, academic institutions and laboratories, and others. The pharmaceutical and biotechnology companies segment was the largest market segment, by end user, with a market value of USD 2,290.4 million in 2017.

Key Insight

The Immunoassays in R&D Market market is projected to grow at a CAGR of 6.7% from 2018 to 2030.

Market Performance Trend

Historical performance and future projections (2020–2030, USD Billion)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Market Scope & Coverage

What this report covers

Geographic Coverage: This analysis covers 4 regions: North America, Europe, Asia Pacific, Rest of the World.
Market Segmentation: The market is analyzed across 3 segments: Kits and Reagents, Analyzers, Software And Services. Forecasts are provided for each segment from 2018 to 2030.
Competitive Landscape: 10 leading companies are profiled, covering market positioning, strategies, and recent developments.

Market Size (USD Mn)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Market Overview

Immunoassays in R&D Market — Growth Trajectory

Immunoassays are analytical methods in which the quantitation of the analyte depends on the reaction of an antigen and an antibody. Immunoassays incorporate a variety of different labels for the detection of antibodies and antigens. These labels are generally chemically linked or conjugated to the desired antibody or antigen. Immunoassays are extensively used in several areas of pharmaceutical research such as therapeutic drug monitoring, disease diagnosis, clinical pharmacokinetic, and bioequivalence studies in drug discovery, among others. Recently, there are numerous improvements in the field of immunoassay which is likely to contribute to market growth.

To provide a detailed analysis of the market structure along with the historical data for five years of various segments and sub-segments of the global immunoassay in R&D marketTo provide insights into factors affecting market growthTo provide historical revenue of market segments and sub-segments with respect to regions and their respective key countriesTo provide country-level analysis of the market with respect to the current market size and prospectsTo provide country-level analysis of the market by product and service, type, application, and end userTo provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape of the marketTo track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and development in the global immunoassay in R&D market

Immunoassays in R&D Market — Growth Trajectory

Kits and Reagents

Analyzers

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Market Size Trend (USD Mn)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Market Dimensions

How this market is segmented

By Product and Services is analyzed as a distinct market dimension.
By Application is analyzed as a distinct market dimension.
By Type is analyzed as a distinct market dimension.
By End User is analyzed as a distinct market dimension.

Geographic Analysis

Regional market breakdown

North America market size reached $6.64B in 2018 and is projected to reach $13.83B by 2030, growing at a CAGR of 6.3%.
Europe market size reached $4.49B in 2018 and is projected to reach $10.08B by 2030, growing at a CAGR of 7.0%.

Asia Pacific market size reached $2.86B in 2018 and is projected to reach $7.23B by 2030, growing at a CAGR of 8.0%.
Rest of the World market size reached $2.02B in 2018 and is projected to reach $3.58B by 2030, growing at a CAGR of 4.9%.

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Research Methodology

Immunoassays in R&D Market — How We Researched This Market

Wantstats analysis is based on interviews with industry experts who offer insight into the market structure, market segmentation, technology assessment, competitive landscape (CL), market penetration, as well as the emerging trends. Besides primary interviews (~80%) and secondary research (~20%), their analysis is based on years of professional expertise in their respective industries. Our analysts also predict where the market will be headed in the next five to 10 years, by analyzing historical trends and the current market position. Furthermore, the varying trends in segments and categories in each region are studied and estimated based on primary and secondary research.

Primary Research

Extensive primary research was conducted to gain a deeper insight into the market and industry performance. For this particular report, we have conducted primary surveys (interviews) with the key level executives (VPs, CEOs, marketing directors, and business development managers, among others) of the major players active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed in the next five to 10 years.

Secondary Research

Secondary research was mainly used to collect and identify information useful for an extensive, technical, market-oriented, and commercial study of the global immunoassay in R&D market. It was also used to obtain key information about major players, market classification and segmentation according to industry trends, and developments related to the market and technology. For this study, analysts have gathered information from various credible sources such as American Association of Immunologists (AAI), American Autoimmune Related Diseases Association (AARDA), Spanish Society for Immunology, Association of Medical School Microbiology and Immunology Chairs (AMSMIC), British Society for Allergy & Clinical Immunology (BSACI), Society for Immunotherapy of Cancer (SITC), German Institute of Medical Documentation and Information (DIMDI), Canadian Society for Immunology (CSI), Expert Interviews, Annual Reports, SEC filings, Research Journals, White Papers, Corporate Presentations, Company websites, Wantstats Analysis, and paid databases.

Market Size Estimation

Both the top-down and bottom-up approaches were used to estimate and validate the size of the market and to estimate the size of various other dependent sub-markets of the overall global immunoassay in R&D market. The key players in the market were identified through secondary research, and their market contributions in different applications across the globe were determined through primary and secondary research. This entire process included the study of the annual and financial reports of the top market players and extensive interviews for key insights with industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All the possible parameters that affect the market covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to arrive at the final quantitative and qualitative data. This data has been consolidated, and detailed inputs and analysis from Wantstats added before being presented in this report. The following figure shows an illustrative representation of the overall market size estimation process employed for this study.

Base Year
2021
Historical Period
2018 – 2020
Forecast Period
2022 – 2030
Primary Interviews
150+

Research Process

Historical data (2018–2021) and forecast period (2021–2030)

Problem Definition

Market scoping
Objective setting
Framework design

Secondary Research

Literature review
Data mining
Trend analysis

Primary Research

Expert interviews
Field visits
Surveys

Data Analysis

Quantitative modeling
Statistical testing
Validation

Insights & Reporting

Synthesis
Recommendations
Visualization

Research Depth

Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.

Historical vs. Forecast Data

Historical (observed)

Forecast (modelled)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Competitive Landscape & Porter's Five Forces

Immunoassays in R&D Market — Competitive Analysis

The immunoassay in R&D market is highly competitive with mainly global and regional players operating in the market. It is decisive for companies in the market to provide cost-efficient products to survive and succeed in an intensely competitive market environment.

The above diagram displays the market share generated by companies in the global immunoassay in R&D market in the year 2017. The global market was led by F. Hoffmann-La Roche AG with 13.3% followed by Thermo Fisher Scientific Inc. with 11.7%, bioMerieux Inc. with 10.4%, Siemens Healthineers with 8.1%, Abbott Laboratories with 4.3%, Becton, Dickinson and Company with 3.6%, Bio-Rad Laboratories with 2.7% of the market share, and Sysmex Corporation with 1.2% of the market share. Other companies manufacturing immunoassay products and providing software and services accounted for about 55.3% market share in 2017.

F. Hoffman-La Roche accounted for a market share of 13.3% in 2017. The company has a diverse product portfolio for immunoassay including Cobas Analyzer Series, Tina-Quant IgA CSF and Tina-Quant IgM CSF, and homogeneous immunoassays products. Apart from this, the company recently launched its first fully automated Zika IgG immunoassay to help detect the Zika virus.

Thermo Fischer Scientific accounted for a share of 11.7% in the global immunoassay market. The company has an extensive portfolio for immunoassay which includes Enzyme-linked immune sorbent assay (ELISA) kits, western blotting systems and reagents, and Luminex technology multiplex assays, among others.

bioMérieux accounted for a market share of 10.4% in 2017. The share of the company is due to the high adoption of its immunoassay products in R&D laboratories. It has the largest installed base of immunoassay systems in clinical laboratories. For Instance, the company has approximately 35,000 VIDAS systems installed worldwide. Moreover, the company is present in more than 150 countries through 43 subsidiaries and a strong network of distributors.

Siemens Healthineers held a market share of 8.1% in 2017. The company is engaged in strategic merger activities which have helped in strengthening its brand image. The share of the company is mainly due to its immunoassay products brand ADVIA, IMMULITE, and Atellica, among others. Also, the company is involved in successful product launches in recent years.

Abbott Laboratories, Inc. is a prominent player and accounted for a market share of 4.3% in the year 2017. The company has a decent product portfolio for immunoassays. Also, the company is increasing its focus towards new product launches to sustain its market share. For Instance, in October 2017, Abbott Laboratories, Inc. announced the US Food & Drug Administration (FDA) clearance for its Alinity CI-Series instruments for clinical chemistry and immunoassay.

Becton, Dickinson and Company accounted for a market share of 3.6% in the global immunoassay in R&D market. The company has a wide product range for immunoassay. Additionally, the company is involved in strategic partnerships and collaborations.

Bio-Rad Laboratories, Inc. held a market share of 2.7%. The company’s products and solutions portfolio are based on technologies to separate, purify, identify, analyze, and amplify biological matter, such as antibodies, acids, cells, and bacteria among others. The company is actively involved in new product launches to strengthen its market presence in the life science sector.

Sysmex Corporation is increasing its presence in immunoassay products. It accounted for a market share of 1.2% in 2017. The company also offers automated immunochemistry systems, which perform assays on minute sample quantities, reagents for liver fibrosis progression and atopic dermatitis test, and support services for its products. Moreover, the company is involved in the development of new products and launches. In March 2018, Sysmex Corporation launched the Automated High-sensitive Immunoassay System for Research Applications HI-1000.

Other companies accounted for a market share of 55.3% as there are a large number of companies which are engaged in manufacturing ELISA kits, western blotting systems and reagents, and immunoassay analyzers and reagents. Other companies present in the market are Qiagen, Mindray, Quidel Corporation, Agilent Technologies, Merck, DiaSorin, PerkinElmer, Bio-Techne, Ortho-Clinical Diagnostics, and GE Healthcare. Apart from these established companies, there are several medium and small-scale players in the market.

Bargaining Power of Suppliers

The bargaining power of suppliers in the immunoassays in R&D market is medium to high. In this market, the suppliers are instruments parts manufacturers, chemical manufacturers, consumable and accessories manufacturers. There are many major and small manufacturers are providing these materials. Additionally, as it is a fairly consolidated market, there is less scope for price differentiation for the suppliers.

Bargaining Power of Buyers

The bargaining power of buyers is medium to high in the global immunoassays in R&D market. The market has a large number of buyers (i.e., pharmaceutical and biotechnology companies), and many immunoassay manufacturing companies are present to cater to the need of the buyers. Also, most of the buyers are research institutes, and due to the budget constraints, they highly price sensitive. Thus, the buyers can exert moderate pressure on the immunoassay manufacturing companies. Furthermore, the market is characterized by a moderate degree of brand identity.

Threat of New Entrants

The threat of new entrants in the global market is low. Any immunoassay products manufacturing company trying to enter the market is required to accept and abide by the mandatory regulatory standards. The market is characterized by a reasonable degree of brand loyalty. Additionally, huge capital is required to set-up an immunoassay products manufacturing company which further restrains the entry of new entrants in the market.

Threat of Substitutes

The threat of substitutes in the global immunoassays in R&D market is medium. Many immunoassay equipment and products are present in the market and buyer propensity to substitute is moderate due to the high availability of substitutes in this market.

Intensity of Rivalry

The degree of competition in the market is high as the market is highly consolidated. A medium degree of product differentiation among existing players is increasing the intensity of rivalry in the global immunoassays in R&D market. Currently, the market is dominated by Tier I companies.

Quantitative Analysis

Regional Breakdown

Regional market breakdown for Immunoassays in R&D Market.

Regional Market Size (USD Mn)

Market estimates by geography (2030)

USD Mn

InsightNorth America leads with $13.83B by 2030, while Asia Pacific is projected to grow fastest at a 8.0% CAGR.

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Regional Market Data

REGION	2018	2021	2030	CAGR	SHARE
North America	$6.64B	$10.23B	$13.83B	6.3%	40%
Europe	$4.49B	$7.18B	$10.08B	7.0%	29%
Asia Pacific	$2.86B	$4.87B	$7.23B	8.0%	21%
Rest of the World	$2.02B	$2.89B	$3.58B	4.9%	10%
Total	$16.00B	$25.17B	$34.73B	6.7%	100%

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Segment Revenue (2030)

Kits and Reagents

Analyzers

Software And Services

06121723

Kits and Reagents60%
Analyzers23%
Software And Services17%

Total Market Size

$34.73B

Market by Segment (2030)

APPLICATION	REVENUE ($B)	GROWTH RATE	MARKET PENETRATION
Kits and Reagents	$20.73B	6.4%	60%
Analyzers	$8.03B	5.7%	23%
Software And Services	$5.97B	9.5%	17%

* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Empower your Business
with Insights

Save over 20% on
Annual Subscription

Subscribe now

Book a demo

See plans for professionals or small and medium businesses.

Analytics

Immunoassays in R&D Market — Key Findings

Analytical insights on Immunoassays in R&D Market covering market dynamics, competitive landscape, and strategic outlook.

Key Analytical Findings

The Immunoassays in R&D Market market is projected to reach $34.73B by 2030, growing at 6.7% CAGR. The Kits and Reagents segment holds the largest share.

Market Dynamics

Immunoassays are bioanalytical procedures in which the quantitation of the analyte depends on the reaction of an antigen (analyte) and an antibody. Immunoassays have been extensively used in several areas of pharmaceutical analysis such as diagnosis of diseases, therapeutic drug monitoring, and clinical pharmacokinetic and bioequivalence studies in drug discoveries. Factors such as the increasing incidence rate of chronic and infectious diseases, increased research and development investment (R&D), and technological advancements are the major drivers propelling market growth. However, the high cost of immunoassay procedures and the high price of immunoassay systems constrain the growth of the market.

Recently, the immunoassay systems and reagent industry is experiencing rapid technological developments. The most popular technologies in immunoassay include lateral flow immunoassay technology (LFIA), Morffi technology, ultrasensitive immunoassays, superparamagnetic nanoparticles, multiplex immunoassays, and chemiluminescence technology. Among these, the adoption of multiplex bead immunoassay systems has increased tremendously due to its cost-effectiveness and low sample volume requirement for analysis. Furthermore, cartridge-based immunology testing systems are gaining momentum because of their features such as simple operation, compact hardware, and smaller pack sizes.

Market Drivers

The increase in the incidence rates of diseases such as kidney problems, thyroid problems, adrenal gland tumors, and heart ailments is expected to drive the growth of the market indirectly. Coronary diseases and renal failure rates are growing tremendously leading to rising in diagnostic tests for such diseases. For instance, according to the data published by the Centers for Disease Control and Prevention in 2017, the American Heart Association stated in 2015 that every year about 7,35,000 Americans have a heart attack.

Moreover, according to the data published by the Centers for Disease Control and Prevention (CDC), the number of new tuberculosis cases in 2015 were 9,272. Also, according to the statistics published in 2015 by the National Center for Health Statistics (NCHS), the number of visits to physicians’ offices for infectious and parasitic diseases were 16.8 million in the US. The increasing incidence rate of chronic and infectious diseases indirectly pushes the companies to increase their research and development investments to understand the correct treatment option. This creates a high demand for new diagnostic devices with higher accuracy and precise nature. Several chronic diseases also require immediate screening, thus leading to an increase in the number of people undergoing these tests, which would eventually fuel the growth of the market. Therefore, the escalating need for controlling and suppressing the prevalence of major diseases is expected to boost the growth of the market.

The increased investments by various government and non-governmental organizations in research has fuelled the growth of the market. Different countries are increasing their research and development investments to help the pharmaceutical and medical device sector to deliver the best services to the people. For instance, China invested 2% of its GDP in research and development in 2015, in comparison to 2.10% in 2016. Similarly, Norway invested 1.9% of its GDP in R&D in 2015, as compared to 2.03% in 2016. This increase in R&D expenditure in several countries has appealed many key companies to expand their business by launching a new product, opening a subsidiary in a particular country, as well as acquiring local manufacturers and distributors. For instance, in February 2018, bioMérieux acquired Invisible Sentinel, a US-based company specialized in molecular testing.

Moreover, in January 2014, bioMérieux acquired BioFire, thus positioning as a major player in infectious disease diagnostics and strengthening its presence in the US. Also, with the increase in the research expenditure, manufacturers and providers are at a better edge to come up with new technologies which are cost-effective and affordable. This strategy also attracts new entrants and increases the competitive edge among companies, creating an increase in the research for producing better immunoassay systems with high specificity, and increased disease targets.

The number of patients suffering from diseases is growing globally, and the complexity and severity of such conditions are also rising. For instance, according to a 2016 study published in the Journal of Translational Medicine, nearly 12,000 patients are newly diagnosed with bladder cancer annually. Also, around 5000 patients die from the same on an annual basis in Japan. The demand for advanced diagnostic methods is rising with the growing number of patients. Presently, top companies are involved in developing immunoassay platforms with improved capabilities such as higher sensitivity and specificity, and a broad menu of tests. Other major advances introduced to researchers include shorter turnaround times (TAT), higher productivity, and easy operation thereby ensuring efficient detection and determination with accurate results. For instance, in January 2017, Siemens Healthineers announced the Novagnost Zika Virus IgM µ-capture Assay. Also, in December 2018, Thermo Fisher Scientific received the Food and Drug Administration (FDA) clearance for its de novo submission of its QMS Plazomicin Immunoassay. This complementary diagnostic immunoassay measures the concentration of a novel therapeutic antibiotic, plazomicin.

Moreover, in 2016, Nima Labs, Inc. launched a gluten-sensor which is a portable device used to detect gluten in the food sample in merely two minutes. Furthermore, the AgraQuant egg test kit used in laboratories is accurate and reliable enzyme-linked immunosorbent assay (ELISA) that allows to test around 38 samples in 30 minutes. Moreover, the development of condition-specific biomarkers and tests are used to test samples from preclinical trials and clinical trials. For instance, extensive research is held for the development of miniature lab-on-a-chip label-free immunoassay devices. Thus, such technological advancements in the testing industry provide favorable backgrounds for market players to invest in research and expand their product portfolio, eventually leading to market growth.

Market Opportunities

A promising platform of two technologies, namely, microfluidics and immunoassays are extensively explored. Heterogeneous microbead-based immunoassays, homogeneous capillary electrophoresis (CE)-based immunoassays, and heterogeneous surface-based immunoassays are some of the types which could be used in the conventional laboratory testing. Recent research has also shown that this integrated technology could be used in countering bioterrorism threats, detecting false negativity in routine blood bank screening of infectious diseases as well as to develop ovarian biomarkers to cure infertility. Thus, such research may provide a promising tool for automatic, sensitive, and selective measurements in practical applications.

The investment in the global immunoassays in R&D market depends on various factors, including pricing of the products, government support, country-wise demand for the immunoassay products and cost of development.

The opportunities for growth of the immunoassays industry in ROAP (Singapore, Indonesia, Malaysia, Thailand, Australia, New Zealand, and other Asia-Pacific countries) are high due to increasing research and development activities by pharmaceutical and biotechnology companies in these countries. Moreover, as chemiluminescence immunoassay is a blooming segment, increasing investments in chemiluminescence immunoassay technology (CLIA) can be fruitful for the immunoassay products manufacturing companies in the coming years. Likewise, the applications of immunoassay are increasing in infectious diseases and oncology and thus provide large opportunities for established as well as new investors in the market.

Market Restraints

Various immunoassay techniques are used in the diagnostic industry for the detection of antibodies in the blood. These tests are done in the form of a blood test. After testing it is necessary to consult a physician for appropriate treatment. Blood tests are quite expensive, causing it to be unaffordable to the middle-class population in developing economies. For instance, according to a report published in 2015 by the American Board of Internal Medicine, a blood test could cost around USD 200 to USD 1,000 whereas a skin test approximately costs around USD 60 to USD 300. Also, the occurrence of small errors in the procedure could cause a huge loss to both the parties, the patient and the laboratory. Moreover, these tests may not be covered under health insurance, and patients need to pay the amount from their pockets. Hence, unfavorable reimbursement policies and high costs related to immunoassay procedures are restraining the growth of the market.

The cost of immunoassay instruments is considerably high. The high cost of these devices makes it difficult for research laboratories to invest in the same. Moreover, manufacturers are more focused on developing innovative immunoassay instruments for providing better treatments to patients, which leads to an increase in the cost of these devices. For instance, Siemens ADVIA Centaur XP Immunoassay System costs approximately USD 14,000. Additionally, the prices of these devices vary according to the countries. Thus, the high cost of immunoassay instruments and systems may hinder the growth of the market over the forecast period.

Market Challenges

In recent years, the popularity of the ELISA test in the market has increased. This led to the less dependent patient population on other prominent testing techniques. However, market growth is parallelly restricted by limitations associated with ELISA testing. It is often reported that cross-contamination could result in false-positive results, therefore resulting in misdiagnosis. As a result, frequent validation is required which increases the recurring cost.

Additionally, the ELISA test requires skilled technicians to perform the test. Lack of training may lead to inappropriate results. Thus, at the forefront of such challenges in the market, the companies are continuously working towards newer research and development for better results. Thus, these factors pose the role of challenge in market growth.

Market Trends

The main steps of any immunoassay workflow include reagent additions, incubations, wash steps, detection, and data management. Automating these steps reduces time, labor, and human errors while streamlining manual processes and efficiency in the laboratory. Owing to these benefits, the demand for automated immunoassay systems is increasing considerably in recent years.

Additionally, most research labs are likely to consider immunoassay automation in terms of enabling microplate-based assays, in automating separate processing steps such as sample preparation, assay assembly, plate washing, or plate reading.

Moreover, some novel ‘closed’ or ‘semi-closed’ immunoassay automation platforms have achieved high levels of sample-to-result automation using their specific technology in recent years. Some of these automation platforms include BioScale’s VIBE and Gyros GyroLab. These systems have gained momentum from potential users looking for simplification in analytical procedures and improvements in immunoassay performance criteria such as increasing sensitivity, reducing assay time, minimizing assay volumes, and reagent consumption, among others.

Immunochemistry analyzers are used as effective tools in endocrinology, oncology, cardiology, therapeutic drug development and monitoring, infectious disease testing, drugs of abuse testing, and autoimmune diseases. The prominent players in the market are focusing on developing immunoassay equipment with low limits of detection and pg/mL measurements. Moreover, with the development of science and technology, several new features are being continuously added in the systems to increase the speed and sensitivity of tests further. For instance, in September 2017, Siemens Healthineers announced the global commercial availability of its Atellica solution, flexible, scalable, and automation-ready immunoassay analyzers that run up to 440 tests per hour. Also, in October 2015, Quanterix Corporation launched the next generation Simoa 2.0 Ultrasensitive Immunoassay Platform. This platform uses single molecule measurements to access previously undetectable proteins.

Pricing Analysis

Pricing is one of the most important factors for a product to withstand in the global immunoassays in R&D market. The importance is not given to what customer’s likes, but rather what they are ready to pay, which, in turn, generate maximum profit or revenue or market share of the overall industry. The market is driven by the demand for quality immunoassay products with high accuracy. Established players enjoy huge profits and provide products at a relatively cost-effective price.

Additionally, the prices of the immunoassay products vary according to the countries and manufacturers. For instance, Siemens ADVIA Centaur XP Immunoassay System costs approximately USD 14,000. Also, the cost for Thermo Fisher Scientific’s immunoassay detection reagents ranges from USD 85 to USD 350.

Strategic Outlook and Future Directions

The COVID-19 pandemic has significantly and positively impacted the global immunoassays in R&D market. During the pandemic immunoassays were extensively utilized to test for COVID-19. Immunoassays were used to detect the levels of antibodies for SARS-CoV-2 in human serum. Due to the pandemic, extensive R&D efforts were undertaken in order to develop accurate diagnostic products to test for COVID-19 which can be produced at mass, along with development of novel vaccines and drugs to counter the rising number of cases and effects of the virus. Additionally, immunoassays are employed in the production of vaccines to evaluate the titer, purity, affinity, potency, and immunogenic response of the vaccines in both animals and people. This had a positive impact on the market, significantly driving market growth.

The pandemic has impacted the business environment for several organizations worldwide. The supply chain in the global immunoassays in R&D market is the key to fulfilling customer demands. In addition, due to the pandemic, several countries have imposed import and export limitations. This has also affected the healthcare industry as many countries are dependent on other countries for raw material supply and technology transfer. However, regulatory bodies took significant initiatives to ensure efficient supply chain management during the pandemic. Additionally, for immunoassays targeted at COVID-19 testing, there was a shortage of the same as demand for such kits and reagents had skyrocketed, while the production rate and laboratory testing capacities could not cope-up. To overcome such challenges, key players also expanded their manufacturing capabilities to meet demand. For instance, in July 2020, Becton, Dickinson and Company (BC) (US) received USD 24 million investment by the US government to ramp up manufacturing for its BD Veritor SARS-CoV-2 immunoassay tests to cater to global demand. Such initiatives aided in strengthening the supply chain. Similarly, in November 2022, Bio-Techne Corporation (US) also announced its opening of a 52,000 square foot immunoassay manufacturing facility in the US. Hence, the pandemic had moderately impacted the global immunoassays in R&D market.

The COVID-19 pandemic had positively impacted on players operating in the market. This is especially due to the new wave of demand and interest that has come into immunoassays and its applications in COIVD-19 research & vaccines development, and its diagnosis. Players such as BD (US), Roche (Switzerland) and Abbott (US) reported significant increase in sales of its immunoassay products owing to the pandemic. However, as the effects of the pandemic started to diminish, number of cases decline, and majority of the populations got vaccinated and the positive effects on revenue was expected to dry-up and return to normalcy. Hence, the pandemic had a positive impact on the market players.

Market Value by Segment (2030)

Value (USD Mn)

Kits and Reagents

Analyzers

Software And Services

Companies

Key companies profiled in Immunoassays in R&D Market

Profiles of 102 companies operating in the Immunoassays in R&D Market market, including revenue, employee count, and market positioning where available.

Region

Industry

Founded Year

Showing 102 of 102 companies

Abcam plc

Healthcare

Company Headquarters: Cambridge, UK Founded: 1998 Workforce: ~1,750 Company Working: Abcam plc is a global life sciences company that discovers, develops, and distributes high-quality biological reagents and tools for research, drug discovery, and diagnostics. It works across the industry to help life scientists complete their projects more quickly. It collaborates with life science organizations to develop novel binders for drug discovery, in-vitro diagnostics, and therapeutics. It supplies over 110,000 products to two-thirds of the world's life scientists to research protein targets, including antibodies, proteins, lysates, biochemicals, kits, and assays. It has thirteen locations globally and operates in over 130 countries worldwide. It manufactures its products in specialized facilities and sources them from over four hundred partners worldwide.

Sysmex Corporation

Company Headquarters: Kobe, Japan Founded: 1968 Workforce: ~ 8,715 Company Working: Sysmex Corporation (Sysmex) develops, manufactures, sells, and exports/imports diagnostic instruments, reagents, and related software. The company provides products, services, and support to customers in more than 190 countries. Its key customers include national and other public hospitals, private hospitals, universities, research institutes, other medical institutions. Sysmex operates in the domain of healthcare testing, which involves examining blood, urine, and other samples. The company's business is in the domain of in vitro diagnostics (IVD), which is essential to the diagnosis and treatment of diseases. The company operates through various subsidiaries in different parts of the world, including the Americas, EMEA, and Asia-Pacific.

Novavax, Inc.

Company Headquarters: Maryland, US Founded: 1987 Workforce: ~2,500 Company Working: Novavax, Inc. is a biotechnology company that commercializes and develops vaccines to prevent a wide range of infectious diseases. It designs recombinant nanoparticle vaccine technology that produces a strong immune response against a variety of pathogens. It is partnered with leading biopharma organizations, government agencies, research institutions, and foundations, namely the Coalition for Epidemic Preparedness Innovations (US), the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (US), the Serum Institute of India Pvt. Ltd. (India), SK Bioscience (South Korea), CPL Biological (India), and Takeda Pharmaceuticals (US). It has seven research and manufacturing facilities. It has presence in regions namely North America, Europe, and the Middle East and Africa

Cleveland Biolabs, Inc

Healthcare

Company Headquarters: New York, US Founded: 2003 Workforce: ~150 Company Working: Cleveland Biolabs, Inc. is an innovative biopharmaceutical company developing products to address immune system diseases and serious medical needs. It is specialized in offering products such as radiation injury products, immune-oncology, and orphan drugs. It has nine product candidates in its pipeline that have been developing directly through itself or its wholly owned companies, namely Incuron, LLC (US) and Panacela Labs, Inc. (US). It has a proprietary platform, namely the Advanced Immunomodulating Multi-Receptor System (AIMS) platform, which is designed to restore immune homeostasis. Moreover, it has collaboration with government agencies which supports the advanced development and procurement of new medical countermeasures including drugs, vaccines, diagnostics, and medical supplies in order to protect public health from chemical, biological, radiological, and nuclear threats.

SIGA Technologies

Company Headquarters: New York, US Founded: 1995 Workforce: ~50 Company Working: SIGA Technologies (SIGA) is a pharmaceutical business at the commercialization stage that develops and offers antiviral treatments for smallpox, monkeypox, cowpox, and vaccinia complications. The company has an established research and development collaboration with US federal entities. It provides countermeasures to the Strategic National Stockpile (SNS) and the Department of Defense (DoD). TPOXX ("oral TPOXX," also known as "tecovirimat" in certain overseas markets) is the Company's lead product, which it distributes to the US government and international governments (including government-affiliated entities). In addition, the Company sells TPOXX intravenous formulation ("IV TPOXX") to the US Government

Company Headquarters: Maryland, US Founded: 1997 Workforce: ~50 Company Working: Altimmune is a clinical-stage biopharmaceutical business focusing on treating obesity and liver illnesses. The business is working on HepTcell, an immunotherapeutic drug aimed at providing a functional cure for chronic hepatitis B. The company was formed through the merger of PharmAthene, Inc. ("PharmAthene") with the company formerly known as Altimmune

Page 1 of 17

…

Go to page

About the Author

Healthcare Research Team

Healthcare

Our healthcare desk at Wantstats is staffed by a mix of clinical-market analysts and a senior researcher who track drug approvals, device launches, and provider economics as they happen — not just at reporting time. Every figure in this report is checked against primary interviews, regulatory filings, and our own proprietary datasets before it goes to print.

Similar Reports

View all

HealthcareJul 31, 2026

Stoma Ostomy Care Market

HealthcareJul 31, 2026

Ready-to-eat Popcorn Market

HealthcareJul 31, 2026

Organoids and Spheroids Market

Powering the world's best teams.
From next-gen startups to established enterprises.

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.

Immunoassays in R&D Market

Immunoassays in R&D Market Research Report: Size, Share, Trend Analysis By Product and Services (Kits and Reagents, Analyzers, Software And Services), By Application (Infectious Diseases, Cancer Research, Endocrinology, Autoimmune Diseases, Others), By Type (Enzyme-Linked Immunosorbent Assay (ELISA), Enzyme-Linked Immunospot Assay (ELISpot), RadioImmunoassay, Chemiluminescence, Fluoroimmunoassay, Others), By End User (Pharmaceutical Companies, Academic Institutions, Government Institutions) and By Region (North America, Europe, Asia Pacific, Rest of the World) - Growth Outlook & Industry Forecast To 2030

Starting from

$4,950

Immunoassays in R&D Market

Key Insight

Market Performance Trend

Market Scope & Coverage

What this report covers

Immunoassays in R&D Market — Growth Trajectory

Market Size Trend (USD Mn)

Market Dimensions

How this market is segmented

Geographic Analysis

Regional market breakdown

Problem Definition

Secondary Research

Primary Research

Data Analysis

Insights & Reporting

Research Depth

Historical vs. Forecast Data

Competitive Landscape & Porter's Five Forces

Immunoassays in R&D Market — Competitive Analysis

Regional Market Data

Segment Revenue (2030)

Segment Market Share

Market by Segment (2030)

Save over 20% onAnnual Subscription

Key Analytical Findings

Market Dynamics

Market Drivers

Market Opportunities

Market Restraints

Market Challenges

Market Trends

Pricing Analysis

Strategic Outlook and Future Directions

Market Value by Segment (2030)

About the Author

Healthcare Research Team

Market Performance Trend

Immunoassays in R&D Market — Growth Trajectory

Market Size Trend (USD Mn)

Market Dimensions

How this market is segmented

Geographic Analysis

Regional market breakdown

Problem Definition

Secondary Research

Primary Research

Data Analysis

Insights & Reporting

Research Depth

Historical vs. Forecast Data

Competitive Landscape & Porter's Five Forces

Immunoassays in R&D Market — Competitive Analysis

Regional Market Data

Segment Revenue (2030)

Segment Market Share

Market by Segment (2030)

Save over 20% onAnnual Subscription

Key Analytical Findings

Market Dynamics

Market Drivers

Market Opportunities

Market Restraints

Market Challenges

Market Trends

Pricing Analysis

Strategic Outlook and Future Directions

Market Value by Segment (2030)

About the Author

Healthcare Research Team

Save over 20% on
Annual Subscription

Save over 20% on
Annual Subscription